Bariatric metabolic surgery (BMS) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent two prominent therapeutic approaches for obesity and its cardiovascular complications [4,5]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.